Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 5,931 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Mouth Disease Clear all

Conditions: Periodontitis, Chronic
Interventions: Hydrogen Peroxide Gel, 13 weeks, Hydrogen Peroxide Gel, 26 weeks, Scaling and Root planing group; Drug · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Oral Mucositis
Interventions: GC4419 90mg, Placebo; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 86
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Corona, California + 77 more

Conditions: Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms, Primary Peritoneal Carcinoma
Interventions: Fenretinide/LXS + Ketoconazole; Drug
Lead sponsor: South Plains Oncology Consortium; Network
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 3
States / cities: Oklahoma City, Oklahoma • Dallas, Texas • Lubbock, Texas

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: capecitabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: IW-3718, placebo, Standard-dose PPIs QD; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 98
States / cities: Birmingham, Alabama • Dothan, Alabama • Peoria, Arizona + 81 more

Conditions: Major Depressive Episode Associated With Bipolar II Disorder
Interventions: NMRA-335140 80 mg, Placebo; Drug
Lead sponsor: Neumora Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Garden Grove, California + 18 more

Conditions: Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
Interventions: Ice, Normal Saline Solution; Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 99 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Hypertension
Interventions: valsartan + amlodipine; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 571 participants
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Acute Myelogenous Leukemia (AML)
Interventions: AT-406 in combination with daunorubicin and cytarabine; Drug
Lead sponsor: Ascenta Therapeutics; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Chicago, Illinois • Ann Arbor, Michigan • St Louis, Missouri + 2 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Centanafadine; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 9 Years to 12 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Dehydration
Interventions: Distilled water, Medical Food 1, Medical Food 2, Pedialyte, Gatorade; Other
Lead sponsor: W. Larry Kenney; Other
Eligibility: 18 Years to 90 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: EGT0001442, Placebo; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Buena Park, California • Los Angeles, California • Santa Ana, California + 8 more

Conditions: Diabetes Mellitus, Gingival Recession, Generalized, Gingival Recession, Localized
Interventions: Coronally Advance Flap associated with connective tissue graft (CAF+CTG); Procedure
Lead sponsor: Mauro Santamaria; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Observational; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 9
States / cities: New Haven, Connecticut • Honolulu, Hawaii • Chicago, Illinois + 5 more

Conditions: Acute Otitis Media
Interventions: cefdinir (Omnicef), azithromycin; Drug
Lead sponsor: Abbott; Industry
Eligibility: 6 Months to 6 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 30
States / cities: Columbiana, Alabama • Montgomery, Alabama • Ozark, Alabama + 24 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Nystatin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Fresno, California • San Francisco, California • Baltimore, Maryland + 2 more

Conditions: Pulmonary Hypertension, Pulmonary Artery Pressure, Exercise Performance, Air Pollution
Interventions: sildenafil, placebo; Drug · Other
Lead sponsor: Marywood University; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Scranton, Pennsylvania

Conditions: Prostate Cancer
Interventions: VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles; Drug
Lead sponsor: Innocrin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer
Interventions: gemcitabine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2004
U.S. locations: 6
States / cities: Chicago, Illinois • Boston, Massachusetts • Burlington, Massachusetts + 1 more

Conditions: HIV Infections
Interventions: Interferon alfa-n3, Interferon alfa-n1; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 15
States / cities: Los Angeles, California • Redwood City, California • New Haven, Connecticut + 9 more

Conditions: Psoriasis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 50
States / cities: Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more

Conditions: Microbiota, Lung Cancer, Oral Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 25 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Dysphagia, Oral Pharyngeal Cancer
Interventions: Iowa Oral Performance Instrument; Device
Lead sponsor: Jonas Johnson; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Transthyretin (TTR) Amyloid Cardiomyopathy
Interventions: Tafamidis; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,733 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 41
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 20 more

Search by objective public record fields.

Adjunctive Hydrogen Peroxide for Periodontal Therapy

ROMAN: Phase 3 Trial Investigating the Effects of GC4419 on Radiation Induced Oral Mucositis in Head/Neck Cancer Patients

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)

Effects of Amino Acid/Electrolyte-based Beverages on Hydration Status

Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus

Oral Mucosa Wound Healing After Gingival Recession Treatment in Diabetic Patients. A Clinical Study.

Glycemic Observation and Metabolic Outcomes in Mothers and Offspring

A Comparison of Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects With Acute Otitis Media

Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome

Does Sildenafil Increase Exercise Performance in Air Pollution?

Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer

Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Cigarette Smoking and Oral Microbiota

Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy